Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
XFOR
$3.53
$
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Next Earnings
2026-02-25
Beta
0.43
Average Volume
Market Cap
Last Dividend
CIK
0001501697
ISIN
US98420X2027
CUSIP
98420X202
CEO
Adam R. Craig
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
143
IPO Date
2017-11-16
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript | X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript | Seeking Alpha | 2026-02-16 17:57:36 |
| X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 | BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The X4 team will hold a fireside chat on February 12th at 12:30 p.m. | GlobeNewsWire | 2026-02-03 07:00:00 |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 20,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors. | GlobeNewsWire | 2026-02-02 16:01:00 |
| All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy | X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2026-01-12 13:01:25 |
| Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? | X4 Pharmaceuticals, Inc. (XFOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, XFOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. | Zacks Investment Research | 2025-12-24 10:57:11 |
| X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia | X4 Pharmaceuticals is a single-asset biotech built around Mavorixafor. This is approved for WHIM in the US, and the next step is a label expansion for CN. XFOR's 4WARD Phase 3 trial in CN will be key. This could unlock a sizeable TAM across 15,000 patients with moderate-to-severe symptoms. Mavorixafor's initial Phase 2 data showed that once-daily oral doses helped with ANC and may reduce G-CSF exposure. | Seeking Alpha | 2025-12-01 09:09:48 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G | 2026-02-12 | 2026-02-12 | View Filing |
| SC 13G/A | 2026-02-05 | 2026-02-05 | View Filing |
| SC 13G/A | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-07 | 2025-11-07 | View Filing |
| 10-Q | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| SC 13G | 2025-11-03 | 2025-11-03 | View Filing |
| 4 | 2025-10-31 | 2025-10-31 | View Filing |
| 4 | 2025-10-31 | 2025-10-31 | View Filing |
| 4 | 2025-10-31 | 2025-10-31 | View Filing |
| SC 13D/A | 2025-10-29 | 2025-10-29 | View Filing |
| 4 | 2025-10-27 | 2025-10-27 | View Filing |
| 8-K | 2025-10-27 | 2025-10-24 | View Filing |
| 424B5 | 2025-10-24 | 2025-10-24 | View Filing |
| 424B5 | 2025-10-23 | 2025-10-23 | View Filing |
| SC 13G | 2025-10-21 | 2025-10-21 | View Filing |
| SC 13G | 2025-10-03 | 2025-10-03 | View Filing |
| 424B3 | 2025-09-18 | 2025-09-18 | View Filing |
| EFFECT | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-17 | 2025-09-17 | View Filing |
| SC 13G | 2025-09-15 | 2025-09-15 | View Filing |
| S-3 | 2025-09-10 | 2025-09-10 | View Filing |
| S-8 | 2025-09-10 | 2025-09-10 | View Filing |
| D | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-25 | 2025-08-25 | View Filing |
| SC 13G | 2025-08-20 | 2025-08-20 | View Filing |
| SC 13G | 2025-08-19 | 2025-08-19 | View Filing |
| SC 13G | 2025-08-18 | 2025-08-18 | View Filing |
| SC 13D | 2025-08-18 | 2025-08-18 | View Filing |
| SC 13D/A | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 3 | 2025-08-14 | 2025-08-14 | View Filing |
| 3 | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 3 | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13D | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-08 | 2025-08-08 | View Filing |
| SC 13G/A | 2025-07-18 | 2025-07-18 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 424B5 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 3 | 2025-06-03 | 2025-06-03 | View Filing |
| 4/A | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 10-Q | 2025-05-01 | 2025-05-01 | View Filing |
| 8-K | 2025-05-01 | 2025-05-01 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-24 | 2025-04-24 | View Filing |
| 8-K | 2025-04-18 | 2025-04-18 | View Filing |
| S-8 | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-26 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| DEF 14A | 2025-03-24 | 2025-03-24 | View Filing |
| PRE 14A | 2025-03-14 | 2025-03-14 | View Filing |
| 8-K | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| SC 13G/A | 2025-01-31 | 2025-01-31 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| S-8 | 2025-01-16 | 2025-01-16 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2024-11-19 | 2024-11-19 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| 4 | 2024-10-16 | 2024-10-16 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Liquidity Sweep Strategy | 14.55% | 1.28 | 7 | 0.36 | 0.41 | 26.37 |
| Neural Forcast | 11.12% | 1.13 | 20 | 0.72 | 1.01 | 22.95 |
| Quantum Inspired Strategy | 6.06% | 0.99 | 19 | 0.25 | 0.14 | 17.88 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |